We chose to use Cenicriviroc (CVC), a dual CCR2/CCR5 inhibitor being tested in clinical trials for a number of applications including liver fibrosis, HIV and COVID-19 (from https://clinicaltrials.gov: NCT01338883, NCT04334915, NCT03028740, NCT04500418)60–62. The gene discussed is CCR2; the disease is Hepatic fibrosis.